DECLARATION AND POWER OF ATTORNEY FOR UNITED STATES PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name, and

I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if more than one name is listed below) of the subject matter which is claimed and for which a United States patent is sought on the invention entitled

HUMAN PEROXISOMAL THIOESTERASE

the specification of which:	•
/X/ is attached hereto.	
// was filed on as application Serial No	and if this
box contains an X //, was amended on	•
// was filed as Patent Cooperation Treaty international application No, 19, if this box contains an X / /, was amended on under Patent C Treaty Article 19 on19, and if this box contains an X / /, was amended on under Patent C Treaty Article 19 on19, and if this box contains an X / /, was amended on under Patent C Treaty Article 19 on19, and if this box contains an X / /, was amended on under Patent C Treaty Article 19 on19, and if this box contains an X / /, was amended on under Patent C Treaty Article 19 on19, and if this box contains an X / /, was amended on under Patent C Treaty Article 19 on19, and if this box contains an X / /, was amended on under Patent C Treaty Article 19 on19, and if this box contains an X / /, was amended on under Patent C Treaty Article 19 on	_ooperation
·	
I hereby state that I have reviewed and understand the contents of the abspecification, including the claims, as amended by any amendment referred to a	ove-identified above.
I acknowledge my duty to disclose information which is material to the this application in accordance with Title 37, Code of Federal Regulations, §1.5	examination of 6(a).

I hereby claim the benefit under Title 35, United States Code, §119 or §365(a)-(b) of any foreign application(s) for patent or inventor's certificate indicated below and of any Patent Cooperation Treaty international applications(s) designating at least one country other than the United States indicated below and have also identified below any foreign application(s) for patent or inventor's certificate and Patent Cooperation Treaty international application(s) designating at least one country other than the United States for the same subject matter and having a filing date before that of the application for said subject matter the priority of which is claimed:

Country	Number	Filing Date	Priority Claimed
			/_/ Yes /_/ No
3*	· · · · · · · · · · · · · · · · · · ·		./_/ Yes /_/ No

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below.

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in said prior application(s) in the manner required by the first paragraph of Title 35, United States Code §112, I acknowledge my duty to disclose material information as defined in Title 37 Code of Federal Regulations, §1.56(a) which occurred between the filing date(s) of the prior application(s) and the national or Patent Cooperation Treaty international filing date of this application:

Application		Status (Pending,
Serial No.	Filed	Abandoned, Patented)

I hereby appoint the following:

LUCY J. BILLINGS
MICHAEL C. CERRONE

Registration No. 36,749 Registration No. 39,132

respectively and individually, as my attorneys and/or agents, with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith. Please address all communications to:

LUCY J. BILLINGS, ESQ. INCYTE PHARMACEUTICALS, INC. 3174 PORTER DRIVE, PALO ALTO, CA 94304

TEL: 415-855-0555 FAX: 415-845-4166

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States

1608 Queen Charlotte Drive, #5

Sunnyvale, California 94087

Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

*IMPORTANT: Before this declaration is signed, the patent application (the specification, the claims and this declaration) must be read and understood by each person signing it, and no changes may be made in the application after this declaration has been signed.

Sole Inventor or		
First Joint Inventor:	Full name:	JENNIFER L. HILLMAN
	Signature:	Jointy Holling
	Date:	June 1 1997
	Citizenship:	United States of America =
	Residence:	Mountain View, California
	P.O. Address:	230 Monroe Drive, #12 Mountain View, California, 94040
Second Joint Inventor:	Full name:	PURVI SHAH
	Signature:	Purishah
	Date:	Purishah 6/10 .1997
	Citizenship:	India
	Residence:	Sunnyvale, California

P.O. Address:

1997

Third Joint Inventor:

Full name:

NEIL C. CORLEY

Signature:

Date:

lume 10

Citizenship:

United States of America

Residence:

Mountain View, California

P.O. Address:

1240 Dale Avenue, #30

Mountain View, California, 94040

Docket No.: PF-0293-3 DIV

I "Express Mail" mailing label number <u>EL 743 379 939 US.</u> I hereby certify that this document and referenced attachments are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10, addressed to: Commissioner for Patents, Box Patent Application, Washington, D.C. 20231 on / - / S - 0 /

By: Mence Ramos Printed: Nancy Ramos

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Hillman et al.

Title: HUMAN PEROXISOMAL THIOESTERASE

Serial No.: To Be Assigned Filing Date: Herewith

Examiner: To Be Assigned Group Art Unit: To Be Assigned

Commissioner for Patents Washington, D.C. 20231

CERTIFICATE UNDER 37 C.F.R. §3.73(b), REVOCATION OF POWER OF ATTORNEY AND APPOINTMENT OF NEW ATTORNEYS

Sir:

The undersigned has reviewed all the documents in the chain of title of the above-identified patent application and, to the best of undersigned's knowledge and belief, title is in the assignee identified above.

Incyte Genomics, Inc., formerly known as Incyte Pharmaceuticals, Inc., having a principal place of business located at 3160 Porter Drive, Palo Alto, California 94304, certifies that it is the assignee and owner of the entire right, title and interest in, to, and under the invention described and claimed in the above-identified application by virtue of an Assignment recorded at Reel 8929, Frame 0266, hereby revokes all previous powers of attorney and appoints the following patent attorneys/agents:

Lucy J. Billings	Reg. No. 36,749
Michael C. Cerrone	Reg. No. 39,132
Diana Hamlet-Cox	Reg. No. 33,302
Richard C. Ekstrom	Reg. No. 37,027
Barrie D. Greene	Reg. No. 46,740
Matthew R. Kaser	Reg. No. 44,817

72194

Lynn E. Murry	Reg. No. 42,918
Shirley A. Recipon	Reg. No. 47,016
Susan K. Sather	Reg. No. 44,316
Michelle M. Stempien	Reg. No. 41,327
David G. Streeter	Reg. No. 43,168
Stephen Todd	Reg. No. 47,139
Christopher Turner	Reg. No. 45,167
Peng Ben Wang	Reg. No. 41,420

Please direct all correspondence to:

Legal Department
Incyte Genomics, Inc.
3160 Porter Drive
Palo Alto, California 94304

and direct all telephone calls and facsimile transmissions to:	Shirley A. Recipon
*	ax: (650) 849-8886.
The undersigned (whose title is supplied below) is en	prowered to act on behalf of the

The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true, and that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date: January 18, 2001

By: Lee Bendekgey

VP, General Counsel/Corporate Secretary